Efficacy News and Research

RSS

BioMarin files investigational NDA for PEG-PAL for the treatment of phenylketonuria

BioMarin Pharmaceutical Inc. has announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL (Poly Ethylene Glycol-Phenylalanine Ammonia Lyase), formerly known as Phenylase, for the treatment of phenylketonuria (PKU).

27 Nov 2007

Two phase II clinical trials commence for NeuroDiscovery

NeuroDiscovery Ltd, an Australian neurology-focused research and development company, has announced that two Phase II clinical trials of NSL-101 have commenced.

27 Nov 2007

Many prostate cancer patients receive wrong treatment

Prostate cancer patients often receive treatment that is contraindicated by pre-existing conditions, like urinary or bowel dysfunction, according to a new study.

26 Nov 2007

Pain relief from cannabis depends on how much you smoke

A study by American researchers suggests that smoking a moderate amount of cannabis (marijuana) may relieve pain but smoking high doses may increase pain.

26 Nov 2007

Transcranial magnetic stimulation for depression

For the first time in a large-scale study, transcranial magnetic stimulation has been shown to be an effective, non-drug treatment for major depression.

21 Nov 2007

How can we know early who will benefit from tumor target therapy?

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge.

21 Nov 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

FDA clears Veridex test for the monitoring of metastatic colorectal cancer

Veridex, LLC has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch System to be used as an aid in the monitoring of metastatic colorectal cancer.

21 Nov 2007

Saline irrigation versus saline spray for relief of chronic nasal symptoms

An inexpensive, safe and easy treatment is an effective method for treating chronic nasal and sinus symptoms – more effective, in fact, than commonly used saline sprays, according to a new study from University of Michigan Health System researchers.

20 Nov 2007

Physical therapy in intensive care reduce hospital stays

The American Physical Therapy Association (APTA) cites the results of the first study to show the effectiveness of early physical therapy for patients in a medical intensive care unit (ICU).

19 Nov 2007

New device for screening potential new drug compounds

A new device invented by researchers at the University of Virginia could save pharmaceutical companies significant time and money in screening potential new drug compounds.

19 Nov 2007

Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy

The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously.

19 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

New clinical standards on the treatment of patients with cystic fibrosis

New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.

16 Nov 2007

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.

16 Nov 2007

Freeze-dried grape powder blocks genes linked to colon cancer

Low doses of freeze-dried grape powder inhibit genes linked to the development of sporadic colorectal cancer, University of California, Irvine cancer researchers found.

15 Nov 2007

number of cases of most vaccine-preventable diseases is at an all-time low

A comparison of illness and death rates for 13 vaccine-preventable diseases in the U.S., before and after use of the vaccine, indicates there have been significant decreases in the number of cases, hospitalizations and deaths for each of the diseases examined, according to a study in the November 14 issue of JAMA: The Journal of the American Medical Association.

14 Nov 2007

Exercise and education improves function and symptoms in women with fibromyalgia

An exercise program that incorporates walking, strength training and stretching may improve daily function and alleviate symptoms in women with fibromyalgia, according to a report in the November 12, 2007 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Nov 2007

Back pain often over-treated

The Sydney University researchers, led by Mark Hancock from the University of Sydney Back Pain Research Group, followed 240 patients suffering from acute low back pain from their first visit to their GP through to recovery.

13 Nov 2007

Human Genome Sciences announces positive phase 2 LymphoStat-B results

Human Genome Sciences, Inc. has announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus (SLE).

13 Nov 2007